DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant.

Vaccine

Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, CNRS-UMR7087, Université Pierre et Marie Curie, Bat CERVI, Hôpital Pitié-Salpêtrière, 83 Bd de l'Hôpital, 75013 Paris, France.

Published: March 2006

Virus-like particle (VLP)-based vaccines have provided highly encouraging results in clinical trials while, in contrast, DNA vaccines expressing non-particulate proteins have proven less successful. Seeking to combine the immunogenicity of VLPs and the ease of production of plasmid DNA, we designed DNA vaccines expressing VLPs consisting of the MLV Gag and modified MLV Env proteins displaying T cell epitopes. We show here that such DNA vaccines are remarkably efficient immunogens for inducing cellular immune responses. In contrast to similar plasmids harboring a point mutation preventing VLP formation, they induce protection against a lethal viral challenge in mice. Thus, these "plasmo-retroVLPs" represent a promising second-generation DNA vaccine.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.vaccine.2005.11.034DOI Listing

Publication Analysis

Top Keywords

dna vaccines
16
immune responses
8
vaccines expressing
8
dna
6
vaccines encoding
4
encoding retrovirus-based
4
retrovirus-based virus-like
4
virus-like particles
4
particles induce
4
induce efficient
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!